HOME >> MEDICINE >> NEWS
Jefferson scientists create first animal model of common type of leukemia

Researchers at Jefferson Medical College and the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia have developed the first animal model of the most common type of human leukemia. The new model should enable scientists to gain both a better understanding of the biochemical and molecular mechanisms underlying the disease, chronic lymphocytic leukemia (CLL), while at the same time provide a testing ground for potential new drugs.

"This is a very important discovery because now we have an animal model to use to develop and test new drugs," says Carlo Croce, M.D., professor and chair of microbiology and immunology at Jefferson Medical College of Thomas Jefferson University and director of the Kimmel Cancer Center, who led the work. "The model indicates what initiates the malignancy and provides us with interesting new targets involved in the earliest steps in the disease."

Several years ago, Dr. Croce and his co-workers isolated a gene, TCL-1, located on chromosome 14, and implicated it in several types of human leukemias and lymphomas, such as T-cell CLL and adult T-cell leukemia. These cancers are characterized by chromosomal rearrangements and in turn the uncontrolled proliferation of T-cells, key infection fighting white blood cells. According to Dr. Croce, TCL-1 is also expressed in two other types of cancer: B-cell CLL and B-cell lymphoma.

"We were puzzled by the fact that all B-cell CLL expressed TCL-1," Dr. Croce explains. "Cytogenetically B-cell CLL and B-cell lymphoma do not show the translocations or rearrangements of the TCL-1 gene observed in T-cell tumors." To better understand why, Dr. Croce and his co-workers created transgenic mice in which TCL-1 essentially is put into overdrive in B-cells.

Surprisingly, they found that when the gene is hyperactive, it produces too much of its protein product, resulting in uncontrolled expansion of leukemic cells and a disease identical to human B-cell CLL. "We did not predi
'"/>

Contact: Steve Benowitz
steven.benowitz@mail.tju.edu
215-955-5291
Thomas Jefferson University
21-May-2002


Page: 1 2

Related medicine news :

1. Jefferson Lab medical imager spots breast cancer
2. Jefferson scientists uncover potential trigger of diabetic kidney disease
3. Uric acid may help reduce effects of spinal cord injury, Jefferson researchers find
4. Jefferson scientists help explain statins effects in Alzheimers disease
5. Jefferson scientists find zinc may help prevent esophageal, oral cancers
6. Jefferson virologists coax HIV out of hiding
7. Jefferson scientists find way to see breast cancer activity from outside the body
8. Jefferson and Molecular Targeting Technologies, Inc. scientists create vaccine for wildlife rabies
9. Jefferson scientists use gene therapy to rescue failing hearts in animals
10. Jefferson scientists reveal how some types of rabies invade the brain
11. Jefferson neuroscientists studying new type of Alzheimers drug to halt disease progression

Post Your Comments:
(Date:7/30/2015)... ... July 30, 2015 , ... The Clinical Data Interchange Standards ... to announce that data standards for clinical research in the areas of Schizophrenia, ... website . These three Therapeutic Area (TA) standards were developed per the CDISC ...
(Date:7/30/2015)... New York, NY (PRWEB) , ... July 30, ... ... with Setria®Glutathione and Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water ... Zaca Recovery Chewable as a simple way to get the natural ingredients that ...
(Date:7/30/2015)... Angeles, CA (PRWEB) , ... July 30, 2015 , ... ... cars on an upcoming dedicated web site. As discussed in a June 8, 2015 ... the minor collisions reported so far have been caused by its computer-driven cars, which ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... announce its position as one of Medicare’s top-rated care centers. The video ... the CMS rating system, which monitors health inspections, staffing, and quality measures. ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is a New Way ... Training Capability , World renown body weight trainer, Paul Ziachik, announces today ... dramatically increases a person’s training capability. , The American College of Sports Medicine ...
Breaking Medicine News(10 mins):Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
(Date:7/30/2015)... Wash. and VANCOUVER , ... OGXI ) announced today that it will report its ... 2015. Company management will host a conference call and ... an overview of financial results, clinical development programs and ... the webcast, log on to the Investor Relations page ...
(Date:7/30/2015)... OAKS, Calif. , July 30, 2015  Amgen (NASDAQ: ... Hassan , partner and managing director of Warburg Pincus LLC, ... are pleased to welcome Fred Hassan and the ... the Amgen Board," said Robert A. Bradway , chairman ... and commitment to innovation will serve Amgen well." ...
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
Cached News: